In vivo efficacy of tesevatinib in patient-derived xenograft glioblastoma models may be limited by tissue binding and compensatory signaling

Tesevatinib is a potent oral brain penetrant EGFR inhibitor currently being evaluated for glioblastoma therapy. Tesevatinib distribution was assessed in wild-type (WT) and Mdr1a/b((−/−))Bcrp((−/−)) triple knockout (TKO) FVB mice after dosing orally or via osmotic minipump; drug-tissue binding was as...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Ther
Main Authors: Kizilbash, Sani H., Gupta, Shiv K., Parrish, Karen E., Laramy, Janice K., Kim, Minjee, Gampa, Gautham, Carlson, Brett L., Bakken, Katrina K., Mladek, Ann C., Schroeder, Mark A., Decker, Paul A., Elmquist, William F, Sarkaria, Jann N.
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8172524/
https://ncbi.nlm.nih.gov/pubmed/33785646
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-20-0640
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados